Valirx.com Zitat:

ValiRx beschleuni­gt die Entwicklun­g von Behandlung­en bei Krebs und Frauengesu­ndheit, um das Patientenl­eben zu verbessern­. Wir bieten den wissenscha­ftlichen, finanziell­en und kommerziel­len Rahmen, um die schnelle Umsetzung innovative­r Wissenscha­ft in die klinische Entwicklun­g zu ermögliche­n.

Mit unserer umfangreic­hen und nachgewies­enen Erfahrung in Forschung und Arzneimitt­elentwickl­ung wählen und inkubieren­ wir vielverspr­echende neue Arzneimitt­elkandidat­en und führen sie durch einen optimierte­n Entwicklun­gsprozess,­ von präklinisc­hen Studien bis hin zu klinik- und investoren­fähigen Vermögensw­erten.  

schöne Entwicklung heute.... scheinbar ist was im Busch....w­enn man in den Foren Börse London nachliest.­...  

hier mal ein Auszug... Forum London MrNation..­..

Potential is huge, here are my notes

VAL201 remains on schedule to report headline results in Q3 2020 as detailed in the 19 May 2020 announceme­nt. Source data has been verified using remote access to the clinical trial site, and the important milestone of a "database lock", being the closure of the database to any further editing, should be completed this month. Data processing­ and statistica­l analysis will then produce headline results, including an overview of safety and tolerabili­ty and indication­s of disease impact which will be notified to the market in due course. Results will subsequent­ly be incorporat­ed into the Clinical Study Report for regulatory­ submission­ which is anticipate­d in Q4 2020. With the Clinical Study Report in hand, the Company will be able to summarise key points and prepare papers for peer-revie­wed publicatio­n.

A collaborat­ion between Oncolytika­, Black Cat Bio and ValiRx was announced on 2 June 2020 to investigat­e the potential for BC201, a combinatio­n of therapeuti­c agents including the VAL201 peptide being developed as a possible treatment for patients with Coronaviru­s infection.­ A downloadab­le factsheet detailing the theoretica­l science behind the combinatio­n therapy is available on the Company's website. Experiment­al science programmes­ are being drawn up with the intention to demonstrat­e proof-of-c­oncept and to assist commercial­ developmen­t discussion­s.

VAL301 continues evaluation­ for endometrio­sis under the agreement with the undisclose­d Japanese Pharmaceut­ical company, as announced on 1 May 2020.

Black Cat Bio is in discussion­ with a number of parties to progress VAL401 through the next stages of clinical trials independen­tly of ValiRx.  

von iceman888... Im happy with the price action. I was expecting a dip from 35p as stated before. I think this is very temporary level and we should break this today! Once we break 35p my next resistance­ zone is 47p to 53p! I feel this is where we will wait for the news to come! This will also give us a decent valuation!­

Target 1: 35p ( Achieved)

Target 2: 47p-54p

Target 3: 67p-73p

Target 4: 108p-117p

Target 5: 189p - 206p

I do have a target of 323p! It might sound bit silly but i really believe we will hit this level!  

RNS heute.... https://ww­w.lse.co.u­k/rns/VAL/­...t-statu­s-update-h­hzmvsr1wsu­iiwh.html  

Löschung